Last updated on November 2017

Mild Dementia/Alzheimer's Disease


Brief description of study

Mild Dementia/Alzheimer's Disease

Detailed Study Description

Northern California Research is enrolling participants for a Mild Dementia/Alzheimer's Disease study. The purpose of this study is to see if daily doses of a study medication will improve the symptoms of mild dementia due to Alzheimer's disease. This study medication has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in your body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Alzheimer's disease. This will be assessed by completing a series of assessments where you will be asked questions by the study staff and you will be asked to write down or verbally say the answers.

The design of the study is double-blind, randomized and placebo controlled. A "double blind" study means that the study doctor and the participants who take part won't know which group is administered the study medication and which group is administered placebo. You will not have to stop taking any medications you are currently taking for your cognitive symptoms such as memantine or donepezil; however, you must be on a stable dose or 3 months.

Clinical Study Identifier: TX15471

Contact Investigators or Research Sites near you

Start Over

Iliana Rodriguez

Northern California Research
Sacramento, CA USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.